IMP-16 in Pseudomonas putida and Pseudomonas stutzeri: potential reservoirs of multidrug resistance Production of metallo-b-lactamases (MBLs) is one of the leading carbapenem resistance mechanisms among Gramnegative aerobes. The IMP-and VIM-type enzymes are considered the most widespread as they have been reported from several continents. These enzymes are very often encoded by integron-borne genes with several allelic variants known for each type (Queenan & Bush, 2007). While SPM is the most common MBL type in Brazil and a Pseudomonas aeruginosa epidemic clone has been detected in several Brazilian cities (Gales et al., 2003; Carvalho et al., 2006), IMP and VIM variants have also been described in some isolates of P. aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae (Sader et al., 2005; Penteado et al., 2009). In this study, we report the presence of MBL IMP-16 in carbapenem-resistant Pseudomonas putida and Pseudomonas stutzeri isolates recovered from two children who attended two different hospitals in Rio de Janeiro, Brazil.
Background and Objectives:The circulation of multiresistant bacteria between pediatric intensive care units is a reality and it is necessary to know the profi le of the most prevalent microorganisms to establish effective control measures. The aim of this study is to describe the profi le of imported multiresistant bacteria (MRB) in a pediatric intensive care unit in Rio de Janeiro, according to the geographic region the hospitals. Methods: Nasal and rectal swabs were collected from all patients who remained for more than 12 hours in other units, and were admitted at the four pediatric intensive care units of Prontobaby.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.